Hepatocellular Carcinoma | Disease Landscape & Forecast | G7 | 2025
The hepatocellular carcinoma therapy market is experiencing substantial growth. Angiogenesis inhibitors have played a central role in treating advanced disease, and immunotherapies such as Roche’s atezolizumab plus bevacizumab, Bristol Myers Squibb’s nivolumab plus ipilimumab, AstraZeneca’s durvalumab with or without tremelimumab, and Merck & Co.’s pembrolizumab have added to the treatment armamentarium. Nevertheless, significant unmet need remains, especially in the underserved early-stage setting. We anticipate the entry of immune checkpoint inhibitor-based combinations and the label expansion of existing agents into the early-stage hepatocellular carcinoma setting, expanding treatment options and fueling further sales growth.
Questions answered
- How large are the clinically and commercially relevant drug-treatable hepatocellular carcinoma populations? How will drug-treatment rates change over the forecast period?
- What is the current treatment landscape for hepatocellular carcinoma? What are interviewed experts’ insights on current therapies?
- What are the key emerging therapies in the late-phase pipeline, and how are they expected to impact the market over the 2024-2034 forecast period?
- What are the main drivers and constraints of the hepatocellular carcinoma market, and how will the market evolve over the forecast period?
Geography: United States, EU5, Japan.
Primary research: 19 country-specific interviews with thought-leading medical oncologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed and recurrent incident cases of hepatocellular carcinoma by country, segmented by stage and line of therapy.
Forecast: 10-year, annualized, drug-level sales and patient share of key hepatocellular carcinoma therapies through 2034, segmented by brands / generics / biosimilars and epidemiological subpopulations.
Drug treatments: Coverage of key current and late-phase emerging therapies.
Product description
Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events.
